+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Therapeutics Market - Global Forecast 2026-2032- Product Image
Peptide Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Peptide Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968565
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Peptide Therapeutics Market is projected to reach USD 148.47 Billion in 2026. It is expected to continue growing at a CAGR of 7.44%, reaching USD 228.97 Billion by 2032.

Peptide therapeutics have moved from a specialized drug class into a strategic growth engine for metabolic disease, oncology, endocrinology, rare diseases, and infectious disease research. Their clinical value is supported by established pharmacology: peptides can bind targets with high specificity, offer predictable receptor-mediated activity, and bridge the therapeutic gap between small molecules and biologics.

Commercial and clinical momentum is being reinforced by the global adoption of GLP-1 receptor agonists, continued use of insulin analogs, advances in peptide receptor radionuclide therapy, and expanding pipelines in oral, long-acting, and cell-penetrating peptide formats. For industry leaders, the peptide therapeutics market is increasingly defined by innovation in peptide synthesis, formulation science, drug delivery, analytical characterization, and scalable manufacturing quality.

Transformative Shifts in the Peptide Therapeutics Landscape

The peptide therapeutics landscape is being reshaped by three forces: next-generation delivery systems, manufacturing modernization, and therapeutic expansion beyond traditional endocrine indications. Long-acting injectables, depot formulations, lipidation, cyclization, permeation enhancers, and nanoparticle-enabled delivery are improving dosing convenience, stability, and patient adherence.

At the same time, solid-phase peptide synthesis, liquid-phase hybrid approaches, greener solvents, continuous manufacturing concepts, high-resolution analytics, and advanced purification technologies are improving scalability and product consistency. The competitive frontier is also shifting toward multi-receptor agonists, peptide-drug conjugates, targeted radioligands, antimicrobial peptides, and peptides designed for intracellular signaling pathways or protein-protein interaction targets.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating peptide therapeutics by improving sequence design, structure prediction, target validation, toxicity screening, and developability assessment. AI-enabled models can help prioritize peptide candidates with stronger binding affinity, improved proteolytic stability, lower immunogenicity risk, and more favorable pharmacokinetic profiles before costly wet-lab testing.

The most important cumulative impact is speed and selectivity across discovery and development. AI, machine learning, and generative design are reducing discovery cycles while supporting formulation screening, synthetic route optimization, impurity prediction, and clinical trial stratification. However, responsible adoption depends on high-quality datasets, validated models, regulatory transparency, data governance, and expert human review to ensure reproducibility and patient safety.

Key Regional Insights

North America remains a leading region for peptide therapeutics due to strong biopharmaceutical R&D, established FDA regulatory experience, venture financing, academic translation, and high uptake of metabolic, diabetes, obesity, and oncology therapies. Europe benefits from mature clinical research networks, EMA oversight, advanced GMP manufacturing capabilities, and strong activity across Germany, France, Italy, Spain, and the United Kingdom, supporting both innovative peptide drug development and high-quality production standards.

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in biosciences, contract development and manufacturing, clinical trial capacity, and advanced bioprocessing infrastructure. Latin America is gaining relevance through Brazil and Mexico as access to diabetes, obesity, and specialty care improves, while the Middle East is strengthening tertiary care, precision medicine programs, and hospital-based specialty treatment. Africa presents long-term demand linked to rising noncommunicable disease burden, infectious disease needs, and healthcare access initiatives, although affordability, cold-chain infrastructure, and regulatory capacity remain important adoption factors.

Key Group Insights

Within ASEAN, expanding healthcare coverage, medical tourism, regional manufacturing, and growing clinical research participation are creating demand for affordable peptide medicines and development partnerships. GCC markets are prioritizing specialty care, diabetes management, obesity treatment, and advanced hospital systems, making peptide-based metabolic and endocrine therapies particularly relevant to public health strategies.

The European Union remains influential through centralized regulatory pathways, research funding, pharmacovigilance standards, and quality frameworks that shape global peptide manufacturing. BRICS countries are important for scale, cost-efficient production, large patient populations, and high disease burden, particularly in diabetes, oncology, and cardiovascular-metabolic disorders. G7 markets lead premium innovation, reimbursement influence, and advanced clinical adoption, while NATO-aligned countries increasingly emphasize resilient pharmaceutical supply chains, biomedical preparedness, and secure access to critical medicines.

Key Country Insights

The United States leads peptide therapeutics innovation through FDA approvals, academic-biotech translation, advanced clinical trial infrastructure, and strong demand for GLP-1, insulin analog, oncology, and rare disease therapies. Canada supports clinical research, specialty access, and biologics-focused regulatory capabilities, while Mexico and Brazil are important Latin American markets for diabetes treatment expansion, local partnerships, and broader access to chronic disease therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced healthcare systems, reimbursement frameworks, hospital networks, and strong clinical trial activity, while Russia remains a large pharmaceutical market with localization and access considerations. China and India are scaling peptide manufacturing, active pharmaceutical ingredient capacity, and R&D programs; Japan emphasizes high-quality innovation, aging-related therapeutic demand, and stringent regulatory science; South Korea is advancing biopharma platforms and precision medicine capabilities; and Australia is recognized for early-phase clinical research strength, regulatory efficiency, and academic clinical trial networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated peptide design, scalable manufacturing, and patient-centered delivery. Investments in long-acting formulations, oral peptide technologies, cold-chain optimization, autoinjectors, implantable or depot systems, and device-enabled administration can improve adherence, access, and clinical utility.

Organizations should strengthen AI-enabled discovery, secure high-purity raw material supply, diversify CDMO partnerships, and build regulatory evidence early around safety, immunogenicity, stability, impurities, bioanalytical performance, and comparability. Commercial teams should align access strategies with real-world evidence and outcomes data, especially in obesity, diabetes, oncology, and rare diseases where payer scrutiny, adherence evidence, and long-term safety monitoring are increasingly important.

Research Methodology

This executive summary is developed using a structured secondary research framework aligned with professional market intelligence practices. The analysis synthesizes publicly available regulatory information, clinical development trends, pharmaceutical manufacturing practices, peer-reviewed scientific literature, patent and pipeline indicators, healthcare policy updates, and macro-level healthcare indicators.

Insights are validated through triangulation across therapeutic area adoption, regional healthcare infrastructure, regulatory activity, drug development trends, manufacturing dynamics, and supply chain considerations. The methodology emphasizes data integrity, source reliability, market relevance, and practical decision support while avoiding unsupported projections, unverified claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Peptide therapeutics are entering a high-value phase defined by clinical specificity, improved delivery, scalable synthesis, and expanding use across chronic and specialty diseases. The field is no longer limited to injectable endocrine drugs; it now includes multi-functional peptides, targeted radioligands, antimicrobial candidates, peptide-drug conjugates, and precision-targeted modalities.

Organizations that combine AI-enabled discovery, robust manufacturing, regulatory discipline, quality-by-design principles, and access-focused commercialization will be best positioned to lead. As demand rises across established and emerging healthcare systems, peptide therapeutics will remain a critical pillar of next-generation pharmaceutical innovation and precision medicine.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Peptide Therapeutics Market, by Peptide Type
7.1. Introduction
7.2. Native Peptides
7.2.1. Hormonal Peptides
7.2.2. Neuropeptides
7.3. Modified Peptides
7.3.1. Cyclized Peptides
7.3.2. PEGylated Peptides
7.3.3. Lipidated Peptides
7.4. Functional Peptides
7.4.1. Antimicrobial Peptides
7.4.2. Cell Penetrating Peptides
8. Peptide Therapeutics Market, by Synthesis Technology
8.1. Introduction
8.2. Biological Synthesis
8.3. Chemical Synthesis
8.3.1. Solid Phase Peptide Synthesis
8.3.2. Liquid Phase Peptide Synthesis
9. Peptide Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Parenteral
9.2.1. Intramuscular
9.2.2. Intravenous
9.2.3. Subcutaneous
9.3. Non Parenteral
9.3.1. Oral
9.3.2. Nasal
9.3.3. Pulmonary
9.3.4. Transdermal
10. Peptide Therapeutics Market, by Application
10.1. Introduction
10.2. Cardiovascular Diseases
10.2.1. Heart Failure
10.2.2. Hypertension
10.3. Infectious Diseases
10.3.1. Bacterial Infections
10.3.2. Viral Infections
10.4. Metabolic Disorders
10.4.1. Diabetes
10.4.2. Obesity
10.4.3. Endocrine Disorders
10.5. Oncology
10.5.1. Breast Cancer
10.5.2. Lung Cancer
10.5.3. Melanoma
11. Peptide Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Peptide Therapeutics Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Peptide Therapeutics Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Peptide Therapeutics Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AmbioPharm Inc.
16.2. Amgen Inc.
16.3. AstraZeneca PLC
16.4. Aurigene Pharmaceutical Services Limited
16.5. Bachem Holding AG
16.6. Bicycle Therapeutics plc
16.7. Bristol-Myers Squibb Company
16.8. CordenPharma International GmbH
16.9. CSBio Inc.
16.10. Cybrexa Therapeutics, Inc.
16.11. Eli Lilly and Company
16.12. Ferring Pharmaceuticals A/S
16.13. GlaxoSmithKline PLC
16.14. Ipsen S.A.
16.15. Ironwood Pharmaceuticals, Inc.
16.16. Mainline Biosciences LLC
16.17. Novartis AG
16.18. Novo Nordisk A/S
16.19. Oncopeptides AB
16.20. Peptech Biosciences Ltd.
16.21. Peptide Institute, Inc.
16.22. PeptiDream Inc.
16.23. PolyPeptide Group AG
16.24. Protagonist Therapeutics, Inc.
16.25. Sanofi S.A.
16.26. SELLAS Life Sciences Group, Inc.
16.27. Takeda Pharmaceutical Company Limited
16.28. Teva Pharmaceutical Industries Ltd
16.29. Zealand Pharma A/S
List of Figures
FIGURE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NATIVE PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HORMONAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROPEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROPEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROPEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MODIFIED PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CYCLIZED PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PEGYLATED PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL LIPIDATED PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FUNCTIONAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CELL PENETRATING PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CHEMICAL SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SOLID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LIQUID PHASE PEPTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NON PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NON PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL NON PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PULMONARY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PULMONARY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PULMONARY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL OBESITY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL OBESITY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL OBESITY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 147. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 148. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 149. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 150. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 151. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 154. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 155. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 157. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 158. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 159. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 160. EUROPE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 189. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 195. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 196. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 197. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 198. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 199. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 200. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 202. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 203. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 204. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 205. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 206. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 207. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 208. AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 224. MIDDLE EAST PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 228. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 229. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 230. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 231. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 232. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 233. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 235. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 236. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 237. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 238. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 239. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 240. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 241. NATO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 244. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 245. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 246. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 247. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 248. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 249. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 251. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 252. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 254. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 255. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 256. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 257. G7 PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 260. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 261. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 262. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 263. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 264. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 265. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 267. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 268. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 270. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 271. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 272. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 273. BRICS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 291. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 292. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 293. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 294. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 295. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 297. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 299. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 300. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 302. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 303. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 304. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 305. ASEAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 306. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 307. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 308. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 309. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 310. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 311. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 313. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 314. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 315. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 316. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 317. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 318. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 319. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 320. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 321. GCC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 323. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 325. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 326. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 327. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 328. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 329. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 330. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 331. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 332. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 333. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 334. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 335. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 336. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 337. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 338. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 341. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY NATIVE PEPTIDES, 2017-2032 (USD MILLION)
TABLE 342. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MODIFIED PEPTIDES, 2017-2032 (USD MILLION)
TABLE 343. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY FUNCTIONAL PEPTIDES, 2017-2032 (USD MILLION)
TABLE 344. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY SYNTHESIS TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 345. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, 2017-2032 (USD MILLION)
TABLE 346. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 347. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 348. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY NON PARENTERAL, 2017-2032 (USD MILLION)
TABLE 349. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 350. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2017-2032 (USD MILLION)
TABLE 351. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 352. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 353. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 354. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 355. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY PEPTIDE TYPE, 2017-2032 (USD MILLION)
TABLE 357. JAPAN PEPTIDE THERAPEUT

Companies Mentioned

  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurigene Pharmaceutical Services Limited
  • Bachem Holding AG
  • Bicycle Therapeutics plc
  • Bristol-Myers Squibb Company
  • CordenPharma International GmbH
  • CSBio Inc.
  • Cybrexa Therapeutics, Inc.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals A/S
  • GlaxoSmithKline PLC
  • Ipsen S.A.
  • Ironwood Pharmaceuticals, Inc.
  • Mainline Biosciences LLC
  • Novartis AG
  • Novo Nordisk A/S
  • Oncopeptides AB
  • Peptech Biosciences Ltd.
  • Peptide Institute, Inc.
  • PeptiDream Inc.
  • PolyPeptide Group AG
  • Protagonist Therapeutics, Inc.
  • Sanofi S.A.
  • SELLAS Life Sciences Group, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zealand Pharma A/S

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 148.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 228.97 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Targeting Peptides Market - Global Forecast 2026-2032 - Product Image

Targeting Peptides Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Peptide Oligonucleotide Conjugate Market - Global Forecast 2026-2032 - Product Image

Peptide Oligonucleotide Conjugate Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Peptide Therapeutics - Global Strategic Business Report - Product Image

Peptide Therapeutics - Global Strategic Business Report

  • Report
  • 486 Pages
  • Global
From
Peptide Therapeutics Market Size, Share & Trends Analysis Report by Type, Application, Type of Manufacturers, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2026-2033 - Product Image

Peptide Therapeutics Market Size, Share & Trends Analysis Report by Type, Application, Type of Manufacturers, Route of Administration, Synthesis Technology, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2026-2034 - Product Image

Peptide Therapeutics Market Size, Share, Trends and Forecast by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region, 2026-2034

  • Report
  • 148 Pages
  • Global
From

About the Peptide Therapeutic Market

The Peptide Therapeutic market is a subset of the Proteomics industry, which focuses on the study of proteins and their functions. Peptide Therapeutics are a type of drug that are composed of short chains of amino acids, and are used to treat a variety of diseases. These drugs are typically used to target specific proteins in the body, and can be used to treat conditions such as cancer, diabetes, and autoimmune diseases. Peptide Therapeutics are often used in combination with other drugs, such as chemotherapy, to maximize their effectiveness. The Peptide Therapeutic market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include Amgen, Merck, Novartis, Pfizer, and Sanofi. Other companies such as AbbVie, AstraZeneca, and Eli Lilly are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.